Department of Endocrinology and Metabolism and Center for Human, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
J Clin Endocrinol Metab. 2010 Jan;95(1):338-42. doi: 10.1210/jc.2009-0993. Epub 2009 Nov 13.
Carney complex (CNC) is a familial multiple neoplasia syndrome frequently associated with primary pigmented nodular adrenocortical disease (PPNAD), a bilateral form of micronodular adrenal hyperplasia that leads to Cushing's syndrome (CS). Germline PRKAR1A mutations cause CNC and only rarely isolated PPNAD.
PRKAR1A mutation analysis in two large families with CS and no other CNC manifestations demonstrated a M1V germline mutation; a total of 21 asymptomatic individuals were screened, and mutation carriers were evaluated for CNC. The mutation was expressed in vitro and functionally tested for its effects on protein kinase A function.
Presymptomatic testing identified five first-degree relatives who were M1V carriers and who were all diagnosed with subclinical, mild CS at ages ranging from 20-56 yr. There were no other signs of CNC. In a cell-free system, we detected a shorter compared with the wild-type type 1alpha regulatory subunit of protein kinase A (PRKAR1A) protein (43 kDa). This was not identified in cell lines from the patients or in transfection experiments in HEK293 cells that showed no detectable PRKAR1A protein from the M1V-bearing constructs. In these cells, the mutant mRNA was expressed in a 1:1 ratio.
In two large families, the M1V PRKAR1A mutation resulted in a PPNAD-only phenotype with significant variability both in terms of age of onset and clinical severity. Expression studies showed a unique effect of this sequence change. This study has implications for genetic counseling of carriers of this PRKAR1A mutation and patients with CNC and PPNAD and for the study of PRKAR1A-related tumorigenesis.
Carney 复合征(CNC)是一种家族性多发性肿瘤综合征,常与原发性色素性结节性肾上腺皮质病(PPNAD)相关,这是一种双侧微结节性肾上腺增生形式,导致库欣综合征(CS)。PRKAR1A 种系突变导致 CNC,仅极少数情况下孤立出现 PPNAD。
对两个具有 CS 且无其他 CNC 表现的大型家族进行 PRKAR1A 突变分析,显示 M1V 种系突变;共筛查了 21 名无症状个体,并对突变携带者进行 CNC 评估。该突变在体外表达,并对其对蛋白激酶 A 功能的影响进行功能测试。
在出现症状前的检测中,发现 5 名一级亲属为 M1V 携带者,他们的年龄均在 20-56 岁之间,被诊断为亚临床、轻度 CS。没有其他 CNC 迹象。在无细胞系统中,我们检测到与野生型相比,蛋白激酶 A(PRKAR1A)的 1 型α调节亚基(PRKAR1A)较短的蛋白(43 kDa)。在患者的细胞系或在 HEK293 细胞中的转染实验中均未发现这种情况,这些细胞系中均未从携带 M1V 的构建体中检测到可检测的 PRKAR1A 蛋白。在这些细胞中,突变型 mRNA 以 1:1 的比例表达。
在两个大型家族中,M1V PRKAR1A 突变导致仅出现 PPNAD 表型,在发病年龄和临床严重程度方面均存在显著差异。表达研究显示该序列变化具有独特的影响。这项研究对该 PRKAR1A 突变携带者的遗传咨询以及 CNC 和 PPNAD 患者具有重要意义,并且对 PRKAR1A 相关肿瘤发生的研究也具有重要意义。